Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1980 Nov;18(5):773–779. doi: 10.1128/aac.18.5.773

Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics.

R N Jones, C Thornsberry, A L Barry, R R Packer, C N Baker, R E Badal
PMCID: PMC284090  PMID: 7447431

Abstract

O-Demethylfortimicin A (compound A49759) was tested against 445 bacteria, and the results were compared with those obtained with fortimicin A, amikacin, gentamicin, netilmicin, sisomicin, and tobramycin. A49759 was found to be active and bactericidal against the Enterobacteriaceae, nonfermentative gram-negative bacilli, and Staphylococcus aureus. A49759 was two- to fourfold more active than fortimicin A against most species tested, but generally fourfold less active than amikacin against this population of Pseudomonas aeruginosa (85% inhibited at less than or equal to 16 microgram of amikacin per ml and 85% inhibited at less than or equal to 64 microgram of A49759 per ml). Only amikacin and A49759 were resistant to most aminoglucoside-inactivating enzymes and also had significant antipseudomonal activity. Amikacin was inactivated by aminoglycoside 6'-acetyltransferase, and A49759 was inactivated by aminoglycoside 3-acetyltransferase. The minimal inhibitory concentrations of all tested aminoglycosides were increased by augmenting the inoculum size.

Full text

PDF
776

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Thornsberry C., Jones R. N., Fuchs P. C., Gavan T. L., Gerlach E. H. Cefuroxime, an in vitro Comparison with Six Other Cephalosporins. Proc R Soc Med. 1977;70(Suppl 9):63–71. [PMC free article] [PubMed] [Google Scholar]
  2. D'amato R. F., Thornsberry C., Baker C. N., Kirven L. A. Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin polymyxin B, and carbenicillin. Antimicrob Agents Chemother. 1975 May;7(5):596–600. doi: 10.1128/aac.7.5.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Deushi T., Iwasaki A., Kamiya K., Kunieda T., Mizoguchi T., Nakayama M., Itoh H., Mori T., Oda T. A new broad-spectrum aminoglycoside antibiotic complex, sporaricin. I. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1979 Mar;32(3):173–179. doi: 10.7164/antibiotics.32.173. [DOI] [PubMed] [Google Scholar]
  4. Deushi T., Iwasaki A., Kamiya K., Mizoguchi T., Nakayama M., Itoh H., Mori T. New aminoglycoside antibiotics, sannamycin. J Antibiot (Tokyo) 1979 Oct;32(10):1061–1065. doi: 10.7164/antibiotics.32.1061. [DOI] [PubMed] [Google Scholar]
  5. Girolami R. L., Stamm J. M. Fortimicins A and B, new aminoglycoside antibiotics. IV. In vitro study of fortimicin A compared with other aminoglycosides. J Antibiot (Tokyo) 1977 Jul;30(7):564–570. doi: 10.7164/antibiotics.30.564. [DOI] [PubMed] [Google Scholar]
  6. Jones R. N., Barry A. L., Fuchs P. C., Gavan T. L., Sommers H. M., Gerlach E. H. Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates. Antimicrob Agents Chemother. 1979 Dec;16(6):823–828. doi: 10.1128/aac.16.6.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kurath P., Grampovnik D., Tadanier J., Martin J. R., Egan R. S., Stanaszek R. S., Cirovic M., Washburn W. H., Hill P., Dunnigan D. A. 4-N-Aminoacylfortimicins E. J Antibiot (Tokyo) 1979 Sep;32(9):884–890. doi: 10.7164/antibiotics.32.884. [DOI] [PubMed] [Google Scholar]
  8. Martin J. R., Johnson P., Tadanier J., Goldstein A. Synthesis of 3-O-demethylfortimicins. Antimicrob Agents Chemother. 1980 Nov;18(5):761–765. doi: 10.1128/aac.18.5.761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nara T., Yamamoto M., Kawamoto I., Takayama K., Okachi R., Takasawa S., Sato T., Sato S. Fortimicins A and B, new aminoglycoside antibiotics. I. Producing organism, fermentation and biological properties of fortimicins. J Antibiot (Tokyo) 1977 Jul;30(7):533–540. doi: 10.7164/antibiotics.30.533. [DOI] [PubMed] [Google Scholar]
  10. Okami Y., Hotta K., Yoshida M., Ikeda D., Kondo S., Umezawa H. New aminoglycoside antibiotics, istamycins A and B. J Antibiot (Tokyo) 1979 Sep;32(9):964–966. doi: 10.7164/antibiotics.32.964. [DOI] [PubMed] [Google Scholar]
  11. Price K. E., DeFuria M. D., Pursiano T. A. Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates. J Infect Dis. 1976 Nov;134(Suppl):S249–S261. doi: 10.1093/infdis/135.supplement_2.s249. [DOI] [PubMed] [Google Scholar]
  12. Sato M., Mori Y. Chemical modification of fortimicins: preparation of 4-N-substituted fortimicin B. J Antibiot (Tokyo) 1979 Apr;32(4):371–378. doi: 10.7164/antibiotics.32.371. [DOI] [PubMed] [Google Scholar]
  13. Sato S., Iida T., Okachi R., Shirahata K., Nara T. Enzymatic acetylation of fortimicin A and seldomycin factor 5 by aminoglycoside 3-acetyltransferase I: [AAC(3)-I] of E. coli KY8348. J Antibiot (Tokyo) 1977 Nov;30(11):1025–1027. doi: 10.7164/antibiotics.30.1025. [DOI] [PubMed] [Google Scholar]
  14. Sugimoto M., Ishii S., Okachi R., Nara T. Fortimicins C, D and KE, new aminoglycoside antibiotics. J Antibiot (Tokyo) 1979 Sep;32(9):868–873. doi: 10.7164/antibiotics.32.868. [DOI] [PubMed] [Google Scholar]
  15. Thornsberry C., Barry A. L., Jones R. N., Baker C. N., Badal R. E., Packer R. R. Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycin. Antimicrob Agents Chemother. 1980 Aug;18(2):338–345. doi: 10.1128/aac.18.2.338. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES